Yes you have. Amgen, for instance, delayed releasing positive results.
That might or might not be (you could tell me which results to give me a clue).
But I said small cap for a reason (though I should say small cap, dev stage public as I have before to be precise).
A trial such as DCVax-L P3 is hugely significant to the market. For a large bio, that is much less true. It is also often the case that they will need cash to prep for launch.
For BPs this is not the case. The decision to stay quiet for competitive reasons can be real.
Market Data 
Markets 
